Menthol for Dyspnea Relief in Health and COPD

Last updated: June 5, 2024
Sponsor: KU Leuven
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Strawberry scent

Menthol inhalation

Clinical Study ID

NCT05785026
S66762
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Menthol inhalation (MI) is a novel and promising treatment option for acute relief of dyspnea, however, the underlying ventilatory and/or neural related mechanisms for this relief in symptoms remain unknown. The overall aim of this research project is to systematically examine the mechanisms of dyspnea relief from MI in healthy individuals and those with COPD.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age: 18 years of age or older

  • Able to speak, read, and write Dutch or English

  • Normal pulmonary function: forced expiratory volume in 1 second (FEV1) to forcedvital capacity ratio>0.70; FEV1≥80%predicted (WP1 and 2 only)

  • Non-smoker or former smokers (smoke-free ≥12 months prior to enrolment) (WP1 and 2only)

  • Clinically stable COPD (based on clinical judgment of the study physician that havenot had exacerbations requiring escalation of medical therapy (i.e., short course oforal corticosteroids or antibiotics) within the preceding 14 days (WP3 and 4 only)

Exclusion

Exclusion Criteria:

  • Contraindication to exercise testing (e.g., significant cardiovascular,musculoskeletal, neurological disease; see Table 4 from ERS/ATS consensus statement)

  • Significant pulmonary or extra-pulmonary disease that, based on clinical assessment,could influence dyspnea and/or impair exercise capacity (with the exception of COPDin WP3 and 4)

  • Body mass index <18.5 or >35 kg/m2

  • An ulcer or tumor in the esophagus, a nasal septum deviation, or recentnasopharyngeal surgery

  • Severe facial trauma including cribriform plate disruption (bone separating brainfrom nasal cavity)

  • Allergies to latex and sensitivities to local anesthetics

  • Inability to give informed consent, including those with significant cognitiveimpairment

  • Alcohol consumption within 12 hours of study visit

  • Current smoker*

  • History of early menopause (age <45 years)

  • Pregnancy or desire to become pregnant while in trial

Study Design

Total Participants: 120
Treatment Group(s): 2
Primary Treatment: Strawberry scent
Phase:
Study Start date:
January 01, 2023
Estimated Completion Date:
June 30, 2027

Study Description

The project is structured in 4 work packages (WP), each including a different sample of healthy volunteers (WP1, 2) or patients with COPD (WP3, 4), respectively with a 1:1 female/male ratio in each WP. Each WP will be single-blind, placebo-controlled cross-over trial to investigate the effects of MI compared to placebo in healthy volunteers during resistive loaded breathing (WP1), in healthy volunteers during cycling exercise (WP2), in people with COPD who have dyspnea at rest (WP3), and in people with COPD during cycling exercise (WP4).

Connect with a study center

  • University Hospital Leuven

    Leuven, 3000
    Belgium

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.